Skip to main content
Blackhawk Growth Corp. logo

Blackhawk Growth Corp. — Investor Relations & Filings

Ticker · BLR ISIN · CA09238B3083 LEI · 875500A5R3SVGXL39M70 CSE Financial and insurance activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2022-03-16 Regulatory Filings
Country CA Canada
Listing CSE BLR

About Blackhawk Growth Corp.

https://www.blackhawkgrowthcorp.com/

Blackhawk Growth Corp. operates as an investment issuer, specializing in generating shareholder value through strategic investments in the technology and life sciences sectors. The company focuses on acquiring and developing assets, intellectual property, and projects related to medical technologies, pharmaceuticals, digital health, software, big data, and AI. Blackhawk seeks opportunities that demonstrate global scalability and potential for positive impact on health and human wellbeing. Its core strategy involves providing capital for R&D and commercialization, followed by value realization through mergers, acquisitions, divestments, or spin-outs and public listings on North American stock exchanges.

Recent filings

Filing Released Lang Actions
Material change report (amended) - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 Material Change Report' and details a material change involving an investment by Blackhawk Growth Corp. in a health research platform. It references a news release dated March 15, 2022, and provides a full description of the material change. The form 51-102F3 is a regulatory filing used in Canadian securities regulation to disclose material changes. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement of a material change event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-16 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an investment by MindBio Therapeutics in a health research platform called Quantified Citizen. It discusses the nature of the investment, the companies involved, and some background information about the companies and their activities. There is no financial data, no regulatory filing references, no meeting materials, no voting results, no audit or management reports, no earnings data, and no legal or merger-related content. The document is essentially a corporate announcement about an investment transaction. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is about 5004 characters, which is sufficient for a detailed announcement but does not contain financial statements or detailed reports. Therefore, the classification is CAP with high confidence.
2022-03-16 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 Material Change Report' and details a material change involving an investment and acquisition pathway by Blackhawk Growth Corp. It references a news release dated March 15, 2022, and provides a full description of the material change. The form 51-102F3 is a regulatory filing used in Canadian securities regulation to disclose material changes. The document is relatively short (4101 characters) and focuses on announcing a material change rather than providing comprehensive financial data or detailed reports. Therefore, it fits the category of a Regulatory Filing (RNS) rather than a full report or announcement of a report publication.
2022-03-15 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an acquisition pathway and investment activities related to MindBio Therapeutics and Blackhawk Growth Corp. It discusses strategic business developments, investment rounds, and future plans for acquisitions to accelerate clinical trials and drug development. There are no financial statements, regulatory filings, or detailed financial data presented. The document is not a formal financial report, earnings release, or regulatory filing but rather a corporate announcement about business activities and investment updates. This fits best under the category of Capital/Financing Update (CAP), as it relates to investment and acquisition activities and funding rounds.
2022-03-15 English
Material change report - English.pdf
Regulatory Filings
2022-03-11 English
News release - English.pdf
Regulatory Filings
2022-03-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.